Ipilimumab administration in patients with advanced melanoma and hepatitis B and C

Journal of Clinical Oncology

Volumn 31, Issue 21, 2013, Pages

  Sharma, Anupa ^a   Thompson, John A ^b   Repaka, Aparna ^a   Mehnert, Janice M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CANCER VACCINE; CORTICOSTEROID; DACARBAZINE; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIBODY; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TENOFOVIR;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASYMPTOMATIC DISEASE; AXILLARY LYMPH NODE; BRAIN DAMAGE; BRAIN DISEASE; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG MEGADOSE; EXCISION; HEPATITIS B; HEPATITIS C; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; LYMPH NODE DISSECTION; MALE; MELANOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; MUSCLE METASTASIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; SUBCUTANEOUS NODULE; VIRUS LOAD;

ANTIBODIES, MONOCLONAL; HEPATITIS B; HEPATITIS C; HUMANS; MALE; MELANOMA; MIDDLE AGED;

EID: 84890478215     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.1946     Document Type: Article

References (24)

1. Yeo W, Chan PK, Zhong S, et al: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307, 2000
2. Yeo W, Lam KC, Zee B, et al: Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15: 1661-1666, 2004
3. Lau GK, Leung YH, Fong DY, et al: High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99:2324-2330, 2002
4. Cheng AL, Hsiung CA, Su IJ, et al: Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320-1328, 2003
5. Torres HA, Davila M: Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 9:156-166, 2012
6. Vento S, Cainelli F, Mirandola F, et al: Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 347:92-93, 1996
7. Melisko ME, Fox R, Venook A: Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol) 16:204-205, 2004
8. Tran B, Rosenthal M: Sunitinib induced hepatitis B reactivation. J Malignant Tumors 1:32-34, 2010
9. Chmiel KD, Suan D, Liddle C, et al: Resolution of severe ipilimumabinduced hepatitis after antithymocyte globulin therapy. J Clin Oncol 29:e237-e240, 2011
10. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363:711-723, 2010
11. Wolchok JD, Neyns B, Linette G, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155-164, 2010
12. O'Day SJ, Maio M, Chiarion-Sileni V, et al: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 21:1712-1717, 2010
13. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 364:2517-2526, 2011
14. Weber J: Review: Anti-CLTA-4 antibody ipilimumab-Case studies of clinical response and immune related adverse events. Oncologist 12:864-872, 2007
15. Danilovic DL, Mendes-Correa MC, Lima EU, et al: Correlations of CTLA-4 gene polymorphisms and hepatitis C chronic infection. Liver Int 32:803-808, 2012
16. Han Q, Duan S, Zhang G, et al: Associations between cytotoxic T lymphocyte-associated antigen-4 polymorphisms and serum tumor necrosis factor-α and interferon-γ levels in patients with chronic hepatitis B virus infection. Inflamm Res 60:1071-1078, 2011
17. Schurich A, Khanna P, Lopes AR, et al: Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53:1494-1503, 2011
18. Keler T, Halk E, Vitale L, et al: Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol 171:6251-6259, 2003
19. Nakamoto N, Cho H, Shaked A, et al: Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 5:e1000313, 2009
20. Yeo W, Zee B, Zhong S, et al: Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306-1311, 2004
21. Weinbaum CM, Williams I, Mast EE, et al: Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Morbidity and Mortality Weekly Report Recommendations and Reports, Centers for Disease Control 57:1-20, 2008
22. Lok AS, McMahon BJ: Chronic hepatitis B: Update 2009. Hepatology 50:661-662, 2009
23. Artz AS, Somerfield MR, Feld JJ, et al: American Society of Clinical Oncology provisional clinical opinion: Chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28:3199-3202, 2010
24. Zurawska U, Hicks LK, Woo G, et al: Hepatitis B virus screening before chemotherapy for lymphoma: A cost-effectiveness analysis. J Clin Oncol 30:3167-3173, 2012